Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.

Thomas ZilliSandra JorcanoSamuel BralCarmen RubioAnna M E BruynzeelAngelo OliveiraUfuk Abacioglu Heikki MinnZvi SymonRaymond Miralbell

Published in: Cancer medicine (2020)

At 18 months, urethra-sparing SBRT showed a low toxicity profile, with minimal impact on QoL and favorable biochemical control rates, regardless of overall treatment time (EOD vs QW).

Keyphrases

prostate cancer
radiation therapy
robot assisted
early stage
radical prostatectomy
locally advanced
placebo controlled
randomized controlled trial
clinical trial
combination therapy
minimally invasive